The Participant Registration is online! Looking forward to your participation.
Scan the QR Code to register
2020 CBIIC will be co-hosted by PhIRDA, CAMDI, HKEX and iMeta Health Information Consulting Co., Ltd., supported by Chinese Academy of Medical Sciences, Southern Medicine Economic Research Institute, Suzhou Industrial Park, Zhongguancun Private Equity & Venture Capital Association (ZVCA), Hong Kong Bio-Med Innotech Association (HKBMIA), Institute for Biotechnology and Medicine Industry (IBMI), Japan Pharmaceutical Manufacturers Association (JPMA), BioCentury and China Association for Enterprises with Foreign Investment R&D-based Pharmaceutical Association Committee (RDPAC). Top leading international institutions including Springer Nature and J.P. Morgan has supported previous CBIIC as well. 2020 CBIIC covers the latest analysis of the industry policy, presentation of the cutting-edge innovation project, hot topics of R&D home and abroad and trends of investment. By the end of 2019, CBIIC has attracted over 10,000 participants, 2,100 domestic and foreign pharmaceutical enterprises and 1,500 investment institutions, and 33 new drugs made global first clinical trial data release, 450 innovative projects at home and abroad made roadshows in this events, receiving extensive attention and highly recognized from pharmaceutical industry and investment home and abroad.
Initiated by PhIRDA and RDPAC and collaborated with IQVIA as project research and service partner, Selection of Post COVID-19 Biopharmaceutical Innovative City with Most Investment Value in China (hereinafter referred to as Selection) will be launched. Based on the principles of transparent, traceable and public, combining with the opinions of independent experts, taking cities as basic units, the three parties will build China's biopharmaceutical industry innovation capability evaluation system. The results of the Selection will be released on the 2020 CBIIC to help the government and institution explore and judge the direction of urban pharmaceutical industry development and facilitate the investors to discover the most valuable pharmaceutical ecosystem.